<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645461</url>
  </required_header>
  <id_info>
    <org_study_id>3314</org_study_id>
    <nct_id>NCT02645461</nct_id>
  </id_info>
  <brief_title>Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS</brief_title>
  <acronym>AchALS</acronym>
  <official_title>Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration
      and progressive paralysis. Other studies have revealed defects in skeletal muscle even in
      absence of motor neuron anomalies, focusing on acetylcholine receptors (AChRs) and supporting
      the so-called &quot;dying-back&quot; hypothesis. Outcome of this study will be to understand if the
      endocannabinoid palmitoylethanolamide (PEA) can reduce the rundown of AChRs currents in ALS
      muscle, and if it can modify ALS patients' clinical and electrophysiological parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome:

      Monitoring the efficacy and safety of PEA in the treatment of patients with ALS. Analysis of
      AChR currents and description of the composition of AChRs subunits in ALS muscles

      Design of the Study:

      A randomized controlled blinded study. Patients with sporadic ALS will receive riluzole alone
      or riluzole+PEA in order to investigate the clinical and electrophysiological effects of
      treatment. The expected number of enrolled patients will be 50.

      All patients satisfying the selection criteria will be randomized into two groups: a first
      group will be treated only with riluzole, the second group with riluzole associated with PEA
      (Normast 600 mg microgranular, 2 sachets/day). The randomization will be done stratifying
      patietns according to type of clinical onset (bulbar vs. spinal). The patients will be
      enrolled in the Department of Neurology and Psychiatry, University of Rome &quot;Sapienza&quot;.

      The visits will be performed at 0 (randomization), 3 and 6 months. At each visit the ALS
      Functional Rating Scale-Revised (ALSFRS-R), the percentage of predicted forced vital capacity
      (FVC%), the Medical Research Council (MRC) score for muscle strength limited to the right
      upper limbs, and the compound muscle action potentials (CMAP) from right ulnar and phrenic
      nerves will be assessed. A muscle biopsy will be done at the end of the study. The obtained
      results will be compared with those observed in muscle samples from denervated (non-ALS)
      control patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in pulmonary capacity of ALS patients at 6 months.</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the percentage of predicted forced vital capacity (FVC %) will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.</measure>
    <time_frame>six months</time_frame>
    <description>Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in muscle strength of ALS patients at 6 months.</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the Medical Research Council (MRC) scale score will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in electrophysiological parameters of ALS patients at 6 months</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riluzole 50 mg twice daily in ALS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endocannabinoid palmitoylethanolamide (PEA)</intervention_name>
    <description>Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily</description>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
    <other_name>PEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Riluzole 50 mg twice daily</description>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ALS according to the El-Escorial criteria;

          -  Age&gt; 18 years;

          -  ALS Functional Rating Scale-Revised (ALSFRS- r) score&gt; 20;

          -  Forced Vital Capacity (FVC)&gt; 30%;

          -  Treatment with Riluzole.

        Exclusion Criteria:

          -  Other diseases motor neurons;

          -  Experimental treatments in the previous three months;

          -  Pregnant or breast-feeding;

          -  Contraindications to the use of riluzole;

          -  Patients undergoing tracheostomy, enteral or parenteral supply;

          -  Severe psychiatric disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>January 1, 2016</last_update_submitted>
  <last_update_submitted_qc>January 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Maurizio Inghilleri</investigator_full_name>
    <investigator_title>Associated Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 21, 2016</submitted>
    <returned>January 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

